INTRODUCTION:Hospitalized smokers benefit from tobacco counseling received in hospital only if it continues after discharge. Interactive voice response (IVR) technology may be useful in delivering this care. METHODS: We conducted a randomized controlled trial testing two intensities of follow-up contact using an IVR system; 738 cigarette smokers who received inpatient counseling at an academic medical center were enrolled. Participants were randomized to receive four IVR calls during the first month postdischarge that included the offer of a call back (CB) from a smoking counselor (IVR + CB, N = 368) or 1 IVR call at 2 weeks postdischarge that assessed smoking outcomes without offering any counseling support (IVR, N = 370). All were assessed by human telephone call at 12 weeks. Postdischarge counseling and medication utilization rates and self-reported smoking cessation were assessed at 2 and 12 weeks postdischarge. RESULTS: Of those randomized to IVR + CB, 59% received a CB offer and 34% of those receiving offers accepted. Cessation rates did not differ between IVR + CB and IVR at 2 weeks (39% vs. 39%, rate ratio: 1.02, 95% CI: 0.85-1.22) or 12 weeks (29% vs. 26%, rate ratio: 1.11, 95% CI: 0.90-1.41). Medication use did not differ by group but was higher among those accepting versus declining CB offers (69% vs. 52%, p < .05). CONCLUSIONS: An IVR system is feasible for postdischarge follow-up and support for hospitalized smokers. Participants, especially pharmacotherapy users, took advantage of postdischarge counseling offers, although offers were not associated with increased smoking cessation.
RCT Entities:
INTRODUCTION: Hospitalized smokers benefit from tobacco counseling received in hospital only if it continues after discharge. Interactive voice response (IVR) technology may be useful in delivering this care. METHODS: We conducted a randomized controlled trial testing two intensities of follow-up contact using an IVR system; 738 cigarette smokers who received inpatient counseling at an academic medical center were enrolled. Participants were randomized to receive four IVR calls during the first month postdischarge that included the offer of a call back (CB) from a smoking counselor (IVR + CB, N = 368) or 1 IVR call at 2 weeks postdischarge that assessed smoking outcomes without offering any counseling support (IVR, N = 370). All were assessed by human telephone call at 12 weeks. Postdischarge counseling and medication utilization rates and self-reported smoking cessation were assessed at 2 and 12 weeks postdischarge. RESULTS: Of those randomized to IVR + CB, 59% received a CB offer and 34% of those receiving offers accepted. Cessation rates did not differ between IVR + CB and IVR at 2 weeks (39% vs. 39%, rate ratio: 1.02, 95% CI: 0.85-1.22) or 12 weeks (29% vs. 26%, rate ratio: 1.11, 95% CI: 0.90-1.41). Medication use did not differ by group but was higher among those accepting versus declining CB offers (69% vs. 52%, p < .05). CONCLUSIONS: An IVR system is feasible for postdischarge follow-up and support for hospitalized smokers. Participants, especially pharmacotherapy users, took advantage of postdischarge counseling offers, although offers were not associated with increased smoking cessation.
Authors: Robert D Reid; Kerri-Anne Mullen; Monika E Slovinec D'Angelo; Debbie A Aitken; Sophia Papadakis; Patricia M Haley; Christine A McLaughlin; Andrew L Pipe Journal: Nicotine Tob Res Date: 2009-11-10 Impact factor: 4.244
Authors: Alan J Forster; Loree Boyle; Kaveh G Shojania; Thomas E Feasby; Carl van Walraven Journal: J Gen Intern Med Date: 2009-01-21 Impact factor: 5.128
Authors: Nancy A Rigotti; Yuchiao Chang; Lisa C Rosenfeld; Sandra J Japuntich; Elyse R Park; Hilary A Tindle; Douglas E Levy; Zachary Z Reid; Joanna Streck; Timothy Gomperts; Jennifer H K Kelley; Daniel E Singer Journal: J Gen Intern Med Date: 2017-06-14 Impact factor: 5.128
Authors: Smita Pakhale; Justine Baron; Michael A Armstrong; Avanti Garde; Robert D Reid; Gonzalo Alvarez; Debbie Aitken; Kerri-Anne Mullen; George Wells; Andrew Pipe Journal: Can Respir J Date: 2015-02-03 Impact factor: 2.409
Authors: L Heyworth; K Kleinman; S Oddleifson; L Bernstein; J Frampton; M Lehrer; K Salvato; T W Weiss; S R Simon; M Connelly Journal: Osteoporos Int Date: 2014-02-25 Impact factor: 4.507
Authors: Jeffrey L Fellows; Richard A Mularski; Michael C Leo; Charles J Bentz; Lisa A Waiwaiole; Melanie C Francisco; Kimberly Funkhouser; Catherine M Stoney Journal: Am J Prev Med Date: 2016-10 Impact factor: 5.043
Authors: Nancy A Rigotti; Hilary A Tindle; Susan Regan; Douglas E Levy; Yuchiao Chang; Kelly M Carpenter; Elyse R Park; Jennifer H K Kelley; Joanna M Streck; Zachary Z Reid; Thomas Ylioja; Michele Reyen; Daniel E Singer Journal: Am J Prev Med Date: 2016-10 Impact factor: 5.043
Authors: Nancy A Rigotti; Susan Regan; Douglas E Levy; Sandra Japuntich; Yuchiao Chang; Elyse R Park; Joseph C Viana; Jennifer H K Kelley; Michele Reyen; Daniel E Singer Journal: JAMA Date: 2014-08-20 Impact factor: 56.272
Authors: Sharon A Fitzgerald; Kimber P Richter; Laura Mussulman; Eric Howser; Shadi Nahvi; Kathy Goggin; Nina A Cooperman; Babalola Faseru Journal: Jt Comm J Qual Patient Saf Date: 2016-05